Focus on Your Breakthrough - We Ensure Reliable Drug Delivery

Bringing new innovative inhalation therapies to market is a long and risky process. The interaction of drug and device involves a high degree of complexity where both technical and regulatory requirements must be met. Having this in mind, choosing the ideal nebulizer and device partner can make all the difference and reduce overall development risks.

Focus on your formulation, knowing a reliable partner takes care of the device and supports you through the development.

Rely on PARI as a trusted partner for the most suitable nebulizer - ensuring the best fit to your drug.

Schematic illustration showing the combination of a drug formulation with an eFlow Technology mesh nebulizer for targeted aerosol delivery to the lungs.

Proven Expertise You Can Rely On

Timeline of drug approvals using eFlow Technology across multiple regions.

Why PARI is Your Trusted Partner

Proven Expertise: 20+ years of experience and a strong track record in mesh nebulizer technology
High-End Mesh Technology: eFlow Technology defines the state-of-the-art in performance
Highest Flexibility: A broad platform concept for the most efficient and adaptable nebulizers
End-to-End Support: In-house aerosol services, regulatory and usability expertise for rapid customization
Reliable Supply: High-quality manufacturing at two PARI sites for clinical and commercial success

“We take clinical risk but don’t want to add device risks. That’s why we like it when our portfolio-companies use eFlow.”

Investor (during ATS 2024 podium discussion)

"When I mention that we work with PARI all discussions on device risk at Wallstreet are over."

CEO (during ERS 2024)

Customization is Key

Learn what made Avalyn Pharma decide to go with a customized eFlow Technology nebulizer. Spoiler: ~8.5 min per dose with an eFlow vs ~27 DPI inhalations or 45–60 min on general-purpose nebulizers.

Ongoing Disclosed Projects – Your Success Could Be Next

ARIKAYCE®*
Mycobacterium avium complex (MAC) Lung disease
Progress up to phase ph3PrePh IPh IIPh IIINDA
L-CsA-I
Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation
Progress up to phase ph3PrePh IPh IIPh IIINDA
Inhaled CMS
Non-CF Bronchiectasis
Progress up to phase ph3-plusPrePh IPh IIPh IIINDA
Molgramostim
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Progress up to phase ndaPrePh IPh IIPh IIINDA
ARINA-1
Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation
Progress up to phase ph3PrePh IPh IIPh IIINDA
ARINA-1
Non-CF Bronchiectasis
Progress up to phase ph2PrePh IPh IIPh IIINDA
AP01
Progressive Pulmonary Fibrosis (PPF)
Progress up to phase ph2PrePh IPh IIPh IIINDA
RCT1100
Primary Ciliary Dyskinesia (PCD)
Progress up to phase ph1PrePh IPh IIPh IIINDA

More than 20 undisclosed projects in pre-clinical and
clinical development with various drug classes

Need More Details Before Reaching Out?

Discover how PARI supports you in achieving impactful clinical results and commercial success

Customization
How our platform supports your drug development process
Usability
To improve patient adherence and clinical outcomes
Lasting Reliability
By long-term supply & consistent quality for commercial success
Digital Technologies
To understand how patients take their drug and boost therapy effectiveness

Let`s partner for success!

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.